Great article, very useful. I particularly like the short characterizaton of the banks. It was also interesting to note how the drug companies and defensive stocks haven't recovered as much and, in particular, how relatively Pfizer is on a p/e basis.
Very informative and interesting to one of MAKO's small shareholders. I am still quite confused about the accounting and when revenues and costs are recognized or deferred but hope to learn more about this in the future. Also, I would like some information about the relative costs to the patients or their insurers about MAKO's treatments versus normal surgical procedures.
Sort by:
Latest comments | Highest ratedBuy British or Buy American? [View article]
Carrying the Dollar Upstream [View article]
MAKO Surgical Corp. Q2 2008 Earnings Call Transcript [View article]